Johnson vaccine for those who refuse other vaccines in the United States

Washington – AFP
The US Drug Administration announced, on Thursday, that it will limit the use of the Johnson & Johnson vaccine against the “Corona” virus to adults who refuse to receive the “Pfizer” and “Moderna” vaccines due to “personal concerns” or medical reasons. The agency said it made the decision because of the risk of dangerous clots associated with the Johnson & Johnson vaccine.
For the same reason, the Centers for Disease Control and Prevention, the country’s largest public health oversight body, recommended in December that the “Moderna” and “Pfizer” vaccines should be used instead of Johnson & Johnson. These three vaccines are the only ones allowed in the United States.
This decision was included in the license for emergency use of the “Johnson & Johnson” vaccine.
The administration counted sixty confirmed cases of blood clots in the United States, including nine deaths. Less than 19 million doses of the “Johnson & Johnson” vaccine were given in the country, or about 3 percent of the total doses that were injected.
The rate of stroke as a result of the vaccine was 3.23 per million doses, according to the US Agency.
“However, we are aware that Johnson’s vaccine against Covid-19 still plays a role in responding to the current pandemic,” said Peter Marks, an official at the agency.
The agency cited three examples of people who can still receive the Johnson & Jenson vaccine, which are individuals at risk of severe allergic reactions to RNA vaccines such as Pfizer and Moderna, and who have difficulty accessing the last two vaccines due to lack of access to the last two vaccines. their availability.
Finally, individuals who “have personal concerns about receiving an mRNA vaccine and would therefore remain unvaccinated.”
And the US agency said: It will continue to closely monitor data on all vaccines. “Our work reflects the strength of our monitoring system and our commitment to ensuring that we use science and data in our decisions,” said Peter Marks.